Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed) | PAR 23 033

FAQs: Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19, Clinical Trial Not Allowed)

1) What is this funding opportunity?

The Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) is a National Institutes of Health (NIH) cooperative agreement opportunity to help move promising, advanced HIV-1 vaccine candidates from late-stage preclinical development into a state of readiness for first-in-human clinical testing.

2) What is the official identifier for the opportunity?

Funding Opportunity Number (FOA): PAR-23-033. CFDA: 93.855.

3) What is the main goal of IPCAVD?

The core aim is translation: supporting the practical, regulated development work needed to take vaccine candidates with strong preclinical justification and build a clinic-ready package (manufacturing, testing, quality, and regulatory readiness) so a clinical trial could begin later.

4) Does this award pay for clinical trials?

No. The FOA is designated "Clinical Trial Not Allowed." The program supports work that prepares for clinical testing but does not support conducting clinical trials under this opportunity.

5) What stage of vaccine development is IPCAVD designed for?

It is aimed at HIV-1 vaccine candidates that are beyond basic discovery and already have strong preclinical justification, but need advanced preclinical, CMC, manufacturing, quality, and regulatory work to reach first-in-human readiness.

6) What kinds of activities are supported?

Supported activities focus on late-stage preclinical and CMC (Chemistry, Manufacturing, and Controls) work that often delays entry into the clinic, including technology transfer, preclinical immunogenicity studies and optimization, structured process development for reproducible/scalable manufacturing, analytical assay development (including qualification and validation), pilot/engineering runs, CGMP manufacturing steps, and IND-enabling work and documentation for regulatory submissions.

7) What does "translation" mean in the context of this program?

Translation here means turning a scientifically promising vaccine concept into a development package that meets real-world requirements for regulated manufacturing and regulatory decision-making, so it can credibly move toward first-in-human clinical testing.

8) What is CMC and why is it emphasized?

CMC stands for Chemistry, Manufacturing, and Controls. It is emphasized because CMC readiness (process development, analytical methods, manufacturing controls, and quality systems) is often what blocks or delays promising vaccine candidates from being ready for clinical use.

9) Does IPCAVD support technology transfer?

Yes. The FOA includes support for technology transfer, such as moving a production process from an academic lab into an industrial or contract manufacturing setting.

10) Are preclinical immunogenicity studies included?

Yes. The program supports preclinical immunogenicity studies and optimization to refine the candidate and its performance as part of late-stage preclinical development.

11) What manufacturing development work can be funded?

The FOA supports structured process development to make manufacturing reproducible and scalable, and allows small-scale pilot or engineering runs to reduce manufacturing risk before full CGMP production.

12) What role do analytical assays play in this FOA?

Analytical assay development is a key emphasis, including the work needed to make assays credible for regulated decision-making. This includes qualification, validation, and testing so the assays can support development decisions and regulatory documentation.

13) Can applicants propose pilot or engineering runs?

Yes. Applicants can propose small-scale pilot or engineering runs to de-risk manufacturing prior to full CGMP manufacturing.

14) Does IPCAVD support CGMP manufacturing?

Yes. A major component is support for Current Good Manufacturing Practice (CGMP) manufacturing and the operational steps needed to produce clinical-grade material.

15) What CGMP-related activities are specifically called out?

The FOA includes partnering with pharmaceutical/biotechnology companies and/or Contract Manufacturing Organizations (CMOs), establishing quality assurance (QA) and quality control (QC) oversight, performing fill-finish operations, and completing product release and storage activities.

16) Are partnerships with CMOs allowed or encouraged?

Yes. The FOA explicitly includes partnering with pharmaceutical or biotechnology companies and/or Contract Manufacturing Organizations (CMOs) as part of producing clinical-grade material.

17) What is meant by QA/QC oversight in this program?

Quality assurance and quality control oversight refers to the systems and checks used to ensure manufacturing and testing are performed appropriately for regulated clinical-grade production, including controls needed for product release and compliance with CGMP expectations.

18) Does the program support fill-finish and product release activities?

Yes. Fill-finish operations, product release, and storage activities are specifically included as supported steps toward clinical-grade supply readiness.

19) Are reference standards and stability testing included?

Yes. The FOA explicitly calls out creating reference standards and establishing drug substance and drug product stability testing programs to demonstrate consistency, shelf-life, and readiness for clinical supply management.

20) What is the difference between drug substance and drug product in this FOA context?

The FOA distinguishes stability programs for both drug substance and drug product, reflecting the need to document stability and consistency at different points in the manufacturing and final product lifecycle as part of a clinic-ready package.

21) What regulatory work is supported?

IPCAVD supports IND-enabling studies and preparation for regulatory submissions, including the development of documentation and data packages that would support an Investigational New Drug (IND) application.

22) What does "IND-enabling" mean here?

It refers to the studies and development work needed to justify human exposure and support an IND submission, including validated analytical methods, stability data, and manufacturing records under CGMP, along with nonclinical work required to support clinical exposure.

23) Does the program fund the actual IND submission?

The FOA states it supports preparation for regulatory submissions and the documentation/data packages used to support an IND. It emphasizes building the evidence and records regulators expect before a vaccine can be administered to humans.

24) What is a U19 cooperative agreement, and why does it matter?

U19 is a cooperative agreement mechanism. The FOA notes that this generally means substantial NIH scientific or programmatic involvement during the project period, and that coordination and milestone-driven progress are common expectations.

25) What is the funding instrument type?

The funding instrument is a cooperative agreement.

26) What is the opportunity category and activity category?

Opportunity category: discretionary. Activity category: health.

27) Who is eligible to apply?

Eligibility is broad and includes many domestic applicant types and certain non-U.S. entities. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses.

28) Are foreign organizations eligible?

Yes. The announcement includes non-domestic (non-U.S.) entities (foreign organizations) among eligible categories.

29) Are U.S. territories or possessions eligible?

Yes. U.S. territories or possessions are listed as eligible.

30) Are minority-serving institutions and other specific institution types eligible?

Yes. The announcement highlights eligibility for categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs), among others.

31) Are faith-based or community-based organizations eligible?

Yes. Faith-based or community-based organizations are listed among the additional eligible categories.

32) Are small businesses eligible?

Yes. Small businesses are included as eligible applicants.

33) Are for-profit companies eligible?

Yes. For-profit organizations (other than small businesses) are listed as eligible, and small businesses are also eligible as a separate category.

34) Are federal agencies eligible?

Yes. Eligible federal agencies are included among the eligible categories.

35) What is the listed award ceiling?

The award ceiling is listed at $3,000,000.

36) What is the original closing date?

The original closing date is 2025-03-14.

37) What is the practical outcome a funded project should aim to deliver?

The practical outcome is a clinic-ready development package for a promising HIV-1 vaccine candidate, including credible analytical methods, stability data, reproducible/scalable processes, CGMP manufacturing readiness (and potentially clinical-grade material), quality systems, and IND-supporting documentation, while not conducting a clinical trial under this FOA.

38) Why does the FOA emphasize milestones and coordination?

Because it is a cooperative agreement (U19), which the FOA describes as typically involving substantial NIH involvement and expectations for coordination and milestone-driven progress during the project.

39) Is this program intended to replace basic research funding?

No. Based on the description, it is positioned as a bridge program for candidates beyond basic discovery, focusing on late-stage preclinical, CMC, manufacturing, and regulatory preparation rather than early-stage exploratory research.

40) What disease area and product type does the FOA target?

The FOA targets HIV-1 vaccine candidates, with the overall aim of advancing those candidates toward readiness for first-in-human clinical testing.